Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014
Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014
复制标题
DOI：
10.2105/ajph.2017.304119
复制
发表时间：
2018-01-01
影响因子：
12.7
通讯作者：
Torrone, Elizabeth A.
中科院分区：
文献类型：
--
作者：
Flagg, Elaine W.;Torrone, Elizabeth A.
目标.检测可能受人乳头瘤病毒疫苗影响的性别和年龄组中肛门生殖器疣（AGW）的减少。我们使用15至39岁的美国私人健康保险参保者的医疗保健索赔估计了2006年至2014年期间的年度AGW患病率。我们使用以下之一得出AGW诊断：（1）尖锐湿疣诊断，（2）病毒性疣诊断结合良性肛门生殖器肿瘤诊断或肛门生殖器病变的破坏或切除，或（3）AGW药物治疗结合良性肛门生殖器肿瘤诊断或肛门生殖器病变的破坏或切除。2008年至2014年期间，15至19岁女性的患病率有所下降（年百分比变化[APC] = -14.1%; P < .001），2009年至2014年期间，20至24岁的妇女（APC = -12.9%; P <0.001）和25至29岁的女性（APC = -6.0%; P = 0.001）。我们观察到20至24岁男性的显著下降（APC = -6.5%; P = 0.005）。在所有其他性别和年龄组中，患病率增加或稳定。我们观察到，在最有可能受人乳头瘤病毒疫苗接种影响的年龄组中，女性的AGW降低，而在20至24岁的男性中，AGW降低。年轻男性的患病率下降可能归因于女性接种疫苗的群体保护。
Objectives. To detect decreases in anogenital warts (AGW) among sex and age groups likely to be affected by human papillomavirus vaccination.Methods. We estimated annual AGW prevalence during 2006 to 2014 using health care claims among US private health insurance enrollees aged 15 to 39 years. We derived AGW diagnoses using 1 of the following: (1) condylomata acuminata diagnosis, (2) viral wart diagnosis combined with a benign anogenital neoplasm diagnosis or destruction or excision of an anogenital lesion, or (3) AGW medication combined with a benign anogenital neoplasm diagnosis or destruction or excision of an anogenital lesion.Results. Prevalence decreased during 2008 to 2014 among females aged 15 to 19 years (annual percentage change [APC] = -14.1%; P < .001) and during 2009 to 2014 among women aged 20 to 24 years (APC = -12.9%; P < .001) and among women aged 25 to 29 years (APC = -6.0%; P = .001). We observed significant declines among men aged 20 to 24 years (APC = -6.5%; P = .005). Prevalence increased or was stable in all other sex and age groups.Conclusions. We observed AGW decreases among females in the age groups most likely to be affected by human papillomavirus vaccination and decreases in men aged 20 to 24 years. Decreased prevalence in young men is likely attributable to herd protection from vaccination among females.